Therefore, to address if the changes in the TME induced by the combination of FAP- and Meso-CAR T might have the potential to engage endogenous anti-tumor immunity, 4662 tumor-bearing C57BL/6 were pre-treated with MigR control or FAP-CAR T cells. The gene discussed is FAP; the disease is neoplasm.